U.S. FDA Says Agency Hasn’t Approved Ranbaxy’s Generic Lipitor

The Food and Drug Administration hasn’t approved Ranbaxy Laboratories Ltd. (RBXY)’s generic version of Pfizer Inc. (PFE)’s $10.7 billion Lipitor cholesterol pill, Sandy Walsh, a spokeswoman for the agency, said.

An FDA vendor made a mistake and a statement from the agency announcing the approval of Ranbaxy’s generic drug was distributed in error, Walsh said in an e-mail.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net.

To contact the editor responsible for this story: Adriel Bettelheim at abettelheim@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.